The skin is a complex organ that provides:
Formulation composition, microstructure, and changes after application, such as evaporation of volatile excipients, can significantly influence drug stability and delivery. These factors are evaluated throughout development.
Topical skin formulations range from:
MedPharm typically selects excipients already approved for the intended route of delivery, such as those listed in the FDA Inactive Ingredient Database. This approach minimizes safety concerns, reduces regulatory risk, and limits the need for extensive in vivo safety studies.
To address limitations of commercially available diffusion cells, MedPharm developed MedFlux-HT®, a proprietary high-throughput flow-through diffusion system for evaluating skin and tissue permeation and penetration.
The system is thermostatically controlled to maintain physiological temperature, and receiver-fluid collection is automated to support higher throughput and improved reproducibility.
MedFlux-HT® also uses smaller dosing areas, allowing a greater number of replicates from limited human tissue supplies.
MedPharm provides rapid access to high-quality human skin tissue, including: